Pharma Braces For Potential Landmark Moment For US Drug Price Controls
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.
You may also be interested in...
Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy
Merck will reduce its dependence on oncology and expand in immunology, adding a Phase III-ready TL1A inhibitor for IBD that could reach the market a few years ahead of losing exclusivity for Keytruda.
IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says
Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.
EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.